Literature DB >> 1690536

Suppression of aortic atherosclerosis in cholesterol-fed rabbits by purified rabbit interferon.

A C Wilson1, R G Schaub, R C Goldstein, P T Kuo.   

Abstract

The effectiveness of rabbit interferon in suppressing atherosclerosis was evaluated in rabbits fed a diet containing 1% cholesterol. Ten male New Zealand White rabbits received intramuscular injections of 1 million units of interferon twice a week, while a control group of 10 rabbits received injections of buffer. Both groups had average serum cholesterol levels of over 2000 mg/dl during the 8-week experimental period. Interferon treatment resulted in no significant hypolipidemic effect or changes in lipoprotein composition. Atherosclerotic lesions in aortas were quantified both macroscopically and microscopically. Interferon treatment decreased the grossly visible lesion area significantly from 25 +/- 4% to 8 +/- 1% (mean +/- SEM, p less than 0.005) compared to the untreated group. Microscopic analysis of serial cross-sections of aortic segments revealed significant (p less than 0.01) reductions in both lesion size and frequency in the interferon-treated group. Electron microscopy also showed that interferon treatment reduced the pathological effects of cholesterol feeding. Tissue analysis showed that total aortic cholesterol was reduced by 28% by interferon treatment, while the aortic phospholipid concentration was increased by 25%. The possibility exists that the interferon preparation used contained other biological response modifiers and that the observed effects may be totally unrelated with interferon. These results suggest that the mechanism of atherosclerosis suppression in these cholesterol-fed rabbits is not related to the lowering of serum cholesterol but may be associated with inhibition of lesion initiation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690536     DOI: 10.1161/01.atv.10.2.208

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  8 in total

1.  Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of beta-interferon.

Authors:  D Stephan; H San; Z Y Yang; D Gordon; S Goelz; G J Nabel; E G Nabel
Journal:  Mol Med       Date:  1997-09       Impact factor: 6.354

2.  Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase.

Authors:  D J Conrad; H Kuhn; M Mulkins; E Highland; E Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

3.  Interferon-gamma inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages.

Authors:  Y J Geng; G K Hansson
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

4.  The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury.

Authors:  L Liu; A Lalani; E Dai; B Seet; C Macauley; R Singh; L Fan; G McFadden; A Lucas
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

5.  Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity.

Authors:  S E Roselaar; G Schonfeld; A Daugherty
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

6.  Induction of sustained expression of proto-oncogene c-fms by platelet-derived growth factor, epidermal growth factor, and basic fibroblast growth factor, and its suppression by interferon-gamma and macrophage colony-stimulating factor in human aortic medial smooth muscle cells.

Authors:  T Inaba; T Gotoda; K Harada; M Shimada; J Ohsuga; S Ishibashi; Y Yazaki; N Yamada
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

7.  Effect of crude extract of Bombyx mori coccoons in hyperlipidemia and atherosclerosis.

Authors:  Mir Mahdi Ali; Sarasa Bharati A Arumugam
Journal:  J Ayurveda Integr Med       Date:  2011-04

8.  Attenuated combined action of cyclosporine a and hyperlipidemia on atherogenesis in rabbits by thymoquinone.

Authors:  Ahmed Ragheb; Ahmed Attia; Fawzy Elbarbry; Kailash Prasad; Ahmed Shoker
Journal:  Evid Based Complement Alternat Med       Date:  2011-05-03       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.